WNY Asset Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.73M Buy
5,610
+42
+0.8% +$42.9K 0.6% 25
2026
Q1
$5.12M Buy
+5,568
New +$5.64M 0.53% 35
2025
Q3
$4.28M Buy
5,614
+425
+8% +$316K 0.41% 37
2025
Q2
$4.04M Buy
5,189
+227
+5% +$176K 0.45% 37
2025
Q1
$4.1M Buy
4,962
+171
+4% +$142K 0.49% 38
2024
Q4
$3.7M Sell
4,791
-153
-3% -$127K 0.46% 36
2024
Q3
$4.38M Sell
4,944
-15
-0.3% -$13.5K 0.51% 36
2024
Q2
$4.49M Buy
4,959
+115
+2% +$92K 0.59% 37
2024
Q1
$3.77M Sell
4,844
-15
-0.3% -$10.7K 0.58% 37
2023
Q4
$2.83M Hold
4,859
0.48% 42
2023
Q3
$2.61M Sell
4,859
-5
-0.1% -$2.58K 0.51% 41
2023
Q2
$2.28M Buy
4,864
+10
+0.2% +$4.19K 0.49% 40
2023
Q1
$1.67M Hold
4,854
0.4% 53
2022
Q4
$1.78M Sell
4,854
-215
-4% -$76.2K 0.48% 51
2022
Q3
$1.64M Sell
5,069
-53
-1% -$16.8K 0.6% 45
2022
Q2
$1.66M Sell
5,122
-2
-0% -$600 0.56% 43
2022
Q1
$1.47M Hold
5,124
0.45% 49
2021
Q4
$1.42M Buy
5,124
+100
+2% +$25.4K 0.42% 51
2021
Q3
$1.16M Sell
5,024
-50
-1% -$12.3K 0.4% 54
2021
Q2
$1.16M Buy
5,074
+5
+0.1% +$1K 0.42% 48
2021
Q1
$947K Buy
+5,069
New +$992K 0.38% 51

Other funds holding LLY

WNY Asset Management's LLY Position: Q2 2026 in Review

WNY Asset Management increased its Eli Lilly (LLY) stake by 0.75% in Q2 2026, buying an estimated $42.9K and bringing the position to 5,610 shares worth $6.73M. The position accounts for 0.6% of the portfolio, ranked #25.

WNY Asset Management first reported a position in LLY in Q1 2021 and has held it in 21 quarters since. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • WNY Asset Management held 5,610 shares of Eli Lilly worth $6.73M as of Q2 2026.
  • WNY Asset Management bought 42 Eli Lilly shares in Q2 2026, an estimated $42.9K.
  • Eli Lilly made up 0.6% of WNY Asset Management's portfolio in Q2 2026, its #25 holding.
  • WNY Asset Management first reported a position in Eli Lilly in Q1 2021 and has held it in 21 quarters since.
  • 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on WNY Asset Management's 13F filing for Q2 2026, filed 17 Aug 2026.